• Question: Do you think that the development of nanobots (specific for cancer treatment) is too far behind the development of immunotherapy; so much so that by the time the FDA approve of it, immunotherapy will be better developed?

    Asked by Marshmallow to Dmitry, Iulia, Ollie on 17 Mar 2017.
    • Photo: Dmitry Dereshev

      Dmitry Dereshev answered on 17 Mar 2017:

      We do have this tension between the development of medical treatments and the agencies that need to approve those in order to be readily available for people. I’d imagine you’ll to consider both that and the costs involved in nanobots vs. immunotherapy. One may be developed better than the other, but it’s the affordable treatment that will ultimately be used, not the best-developed one.